Grantees Not In Danger Of Losing Cost-Free Biological Materials, But Can’t Have Chemicals
In Brief: NCI Scientists May Run For Congress; Upton Back Heroin For Terminal Cancer Patients
R. Lee Clark to Retire; Texas Starts Search for Successor
Drugs Available To Investigators Centers to Monitor Them Are Listed
FDA’s Young Still Not Satisfied With Distribution Plan
Tobacco Council Announces Awards
FDA Adopts Final Diagnostics X-Ray Rule Amendment
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
